Key Points
- Wendy Becker, an independent director, bought 3,334 shares of GSK on Feb. 20 at GBX 2,219 each (≈£73,981), and had earlier purchased 441 shares in December at GBX 1,809, signaling insider conviction.
- GSK has a market cap of about £89.7 billion, a 52‑week range of GBX 1,242.50–2,282 and a P/E of 16.72, while analysts hold a consensus "Hold" rating with a target of GBX 1,917.86.
GSK plc (LON:GSK - Get Free Report) insider Wendy Becker acquired 3,334 shares of the stock in a transaction on Friday, February 20th. The shares were acquired at an average cost of GBX 2,219 per share, for a total transaction of £73,981.46.
Wendy Becker also recently made the following trade(s):
- On Friday, December 19th, Wendy Becker bought 441 shares of GSK stock. The stock was acquired at an average cost of GBX 1,809 per share, with a total value of £7,977.69.
GSK Price Performance
Shares of GSK opened at GBX 2,223.16 on Friday. GSK plc has a fifty-two week low of GBX 1,242.50 and a fifty-two week high of GBX 2,282. The company has a market capitalization of £89.70 billion, a price-to-earnings ratio of 16.72, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31. The firm has a 50-day simple moving average of GBX 1,923 and a 200-day simple moving average of GBX 1,722.15. The company has a debt-to-equity ratio of 114.64, a quick ratio of 0.73 and a current ratio of 0.81.
GSK (LON:GSK - Get Free Report) last issued its quarterly earnings results on Wednesday, February 4th. The company reported GBX 172 earnings per share (EPS) for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. On average, equities research analysts anticipate that GSK plc will post 175.980975 earnings per share for the current year.
Key Headlines Impacting GSK
Here are the key news stories impacting GSK this week:
- Positive Sentiment: Investor confidence boost — IBD upgraded GSK’s ADR, a technical/fundamental endorsement that can attract momentum and retail buying. GSK ADR earns IBD stock rating upgrade
- Positive Sentiment: Insider buying — independent director Wendy Becker purchased 3,334 shares at ~GBX 2,219, signaling management/board conviction. Insider purchases often support sentiment. GSK Director Wendy Becker Increases Stake with Share Purchase
- Positive Sentiment: Ongoing buybacks — GSK repurchased 470,000 shares (~£10.5m) recently, modestly supporting EPS and indicating capital return. GSK lifts treasury stake with latest £10.5m share buyback
- Positive Sentiment: Clinical/commercial upside — a real‑world study reported AREXVY (RSV vaccine) is associated with lower risks of heart attack, stroke and severe COPD/asthma exacerbations, which could bolster uptake and long‑term revenue. GSK’s AREXVY Associated With Reductions in Certain RSV-Related Risks
- Positive Sentiment: R&D partnerships — GSK struck multi‑year collaborations with Jackson Laboratory / NYSCF to advance human cellular models and neurodegenerative research, strengthening its pipeline in high‑value areas. These are longer‑term positives for drug discovery. GSK strikes 5-year deal with Jackson Laboratory
- Neutral Sentiment: Trading activity — options activity has spiked on NYSE listings, indicating speculative interest and short‑term volatility rather than a directional fundamental change. GSK Sees Options Surge in NYSE Composite
- Neutral Sentiment: Analyst/market discussion — some market pieces question whether GSK’s recent rally limits upside, which can cool momentum even amid positive fundamentals. Is It Too Late To Consider GSK After Its Strong Share Price Rally?
- Negative Sentiment: Insider selling — former CEO Luke Miels sold 15,579 shares recently; large director/exec sales can weigh on sentiment even if they’re for personal reasons. Luke Miels Sells 15,579 Shares of GSK Stock
Wall Street Analysts Forecast Growth
GSK has been the subject of several analyst reports. JPMorgan Chase & Co. restated an "underweight" rating on shares of GSK in a research note on Wednesday, January 7th. Berenberg Bank boosted their price objective on shares of GSK from GBX 1,600 to GBX 1,660 and gave the company a "hold" rating in a research note on Monday, November 24th. Jefferies Financial Group restated a "buy" rating and set a GBX 2,100 price objective on shares of GSK in a research report on Wednesday, January 7th. Deutsche Bank Aktiengesellschaft raised their target price on shares of GSK from GBX 1,600 to GBX 1,675 and gave the stock a "hold" rating in a research note on Thursday, January 15th. Finally, Shore Capital Group reiterated a "buy" rating and set a GBX 2,300 price target on shares of GSK in a research note on Wednesday, February 4th. Three investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of GBX 1,917.86.
View Our Latest Research Report on GSK
GSK Company Profile
(
Get Free Report)
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
